MSCLF and MSCL Related Headlines
Go Back- Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos launches public offering, files for NASDAQ listing
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Satellos names Antoinette Paone as chief development officer
- Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
- Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Satellos gets FDA clearance for pediatric Duchenne study
- Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in December Investor Conferences
- Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
- Satellos appoints Mark Nawacki to board, advances DMD drug trials
- Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
- Satellos to Participate in November Investor Conferences
MSCLF and MSCL Related Press Releases
Go Back- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
- Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in December Investor Conferences
- Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
- Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
- Satellos to Participate in November Investor Conferences
